Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label multi-site trial designed to evaluate the safety of
administering rapidly-generated Tumor associated antigen specific T cells (TAA-T) with the
Programmed Death1 (PD-1) inhibitor Nivolumab, in relapsed/refractory lymphoma (rel/ref)
patients with measurable disease (group A) or as adjunctive therapy following autologous
hematopoeitic stem cell transplant(HSCT) for patients at high risk of relapse (group B).
The purpose of this study is to find out if the tumor specific T cells given with Nivolumab
are safe and to learn what the side effects are and if the combination can help patients with
relapsed lymphomas.